

## Gene control, delivered directly to the brain , could help cure diseases

A biotech company called [Alnylam](#) announced today that a small clinical trial for a genetic therapy based on RNA interference, or RNAi, suggests that the technique can have a powerful effect on its target gene. The therapeutic effect lasted for over a month with just one dose. The company is also working with a medical device maker, Medtronic, on a way to deliver RNAi treatment directly to the brain, in order to treat the degenerative brain disease Huntington's.

The patients in the trial have a genetic disorder that originates in the liver and leads to the buildup of protein deposits in many organs. [Alnylam](#), a Cambridge, Massachusetts-based company, says its RNAi therapeutic, given at its highest dose, reduces the amount of the faulty protein that spurs the disease by almost 94 percent.

**View the original article here: [Gene Control, Delivered Directly to the Brain – Technology Review](#)**